NO20100301L - Forbedrete brimonidinsammensetninger for behandling av erytem - Google Patents

Forbedrete brimonidinsammensetninger for behandling av erytem

Info

Publication number
NO20100301L
NO20100301L NO20100301A NO20100301A NO20100301L NO 20100301 L NO20100301 L NO 20100301L NO 20100301 A NO20100301 A NO 20100301A NO 20100301 A NO20100301 A NO 20100301A NO 20100301 L NO20100301 L NO 20100301L
Authority
NO
Norway
Prior art keywords
erythema
treatment
improved
brimonidine
compositions
Prior art date
Application number
NO20100301A
Other languages
English (en)
Inventor
Klaus Theobald
Christopher V Powala
Original Assignee
Galderma Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Lab Inc filed Critical Galderma Lab Inc
Publication of NO20100301L publication Critical patent/NO20100301L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Abstract

Foreliggende oppfinnelse angår et farmasøytisk preparat omfattende brimonidintartrat i en mengde fra ca. 0,17 vekt-% til ca. 0,19 vekt-% i en farmasøytisk akseptabel bærer så som en gel eller krem. Oppfinnelsen angår også en metode og/eller anvendelse av behandling av erytem hos en pasient med rosacea ved administrering av preparatet ifølge oppfinnelsen til erytemstedet på huden til pasienten.
NO20100301A 2007-08-31 2010-03-04 Forbedrete brimonidinsammensetninger for behandling av erytem NO20100301L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96719107P 2007-08-31 2007-08-31
PCT/US2008/010290 WO2009032223A1 (en) 2007-08-31 2008-08-29 Improved brimonidine compositions for treating erythema

Publications (1)

Publication Number Publication Date
NO20100301L true NO20100301L (no) 2010-03-25

Family

ID=40407909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20100301A NO20100301L (no) 2007-08-31 2010-03-04 Forbedrete brimonidinsammensetninger for behandling av erytem

Country Status (12)

Country Link
US (3) US20090061020A1 (no)
EP (1) EP2200617A4 (no)
JP (1) JP2010537988A (no)
KR (1) KR20100055453A (no)
CN (2) CN102552112A (no)
AR (1) AR068816A1 (no)
AU (1) AU2008296948A1 (no)
BR (1) BRPI0816097A2 (no)
CA (1) CA2698680A1 (no)
MX (1) MX2010002392A (no)
NO (1) NO20100301L (no)
WO (1) WO2009032223A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
KR101453601B1 (ko) * 2009-05-29 2014-10-22 갈데르마 리써어치 앤드 디벨로프먼트 주입으로 인한 피부 반응 감소를 위한 필러와 아드레날린 수용체 작용제의 주사가능한 조합
EP2493309A4 (en) * 2009-10-26 2013-05-01 Galderma Pharma Sa METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
KR20130010122A (ko) 2010-03-26 2013-01-25 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
KR101707704B1 (ko) 2010-03-26 2017-02-16 갈데르마 리써어치 앤드 디벨로프먼트 홍반의 유효하고 안전한 치료를 위한 개선된 방법 및 조성물
JP2013540142A (ja) * 2010-10-21 2013-10-31 ガルデルマ・ソシエテ・アノニム 局所ゲル組成物
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
CA2814952C (en) 2010-10-21 2016-05-10 Galderma S.A. Brimonidine gel compositions and methods of use
CN107007546A (zh) 2011-02-15 2017-08-04 阿勒根公司 用于治疗红斑痤疮的症状的羟甲唑啉药物乳膏组合物
CA2850273A1 (en) 2011-10-19 2013-04-25 Galderma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
US11278548B2 (en) 2017-07-14 2022-03-22 Galderma Research And Development Methods and compositions for reducing side effects in chemotherapeutic treatments
JP2022531116A (ja) 2019-05-01 2022-07-06 クレキシオ バイオサイエンシーズ エルティーディー． そう痒症を治療する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
GB8827968D0 (en) * 1988-11-30 1989-01-05 Boots Co Plc Sunscreen compositions
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050276765A1 (en) * 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
CA2709199A1 (en) * 2007-12-21 2009-07-02 Galderma Laboratories, Inc. Pre-surgical treatment

Also Published As

Publication number Publication date
CN101808645A (zh) 2010-08-18
EP2200617A4 (en) 2011-01-12
BRPI0816097A2 (pt) 2016-11-01
MX2010002392A (es) 2010-07-28
US20120282346A1 (en) 2012-11-08
JP2010537988A (ja) 2010-12-09
CN102552112A (zh) 2012-07-11
AU2008296948A1 (en) 2009-03-12
US20120040016A1 (en) 2012-02-16
EP2200617A1 (en) 2010-06-30
CA2698680A1 (en) 2009-03-12
US20090061020A1 (en) 2009-03-05
WO2009032223A1 (en) 2009-03-12
KR20100055453A (ko) 2010-05-26
AR068816A1 (es) 2009-12-09

Similar Documents

Publication Publication Date Title
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
NO20064584L (no) Tetrahydropyridoindolderivater
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2013173129A3 (en) Treatment of amd using aav sflt-1
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
WO2009106980A3 (en) Indazole derivatives
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
BR112015007592A2 (pt) composições de enalapril
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application